Permanent Prostate Brachytherapy Monotherapy With I-125 for Low- and Intermediate-Risk Prostate Cancer: Outcome in 966 Patients

被引：4
|
作者：
Funk, R. K. [1 ]
Davis, B. J. [1 ]
Mynderse, L. A. [1 ]
Wilson, T. M. [1 ]
Deufel, C. L. [1 ]
Furutani, K. M. [1 ]
Pisansky, T. M. [1 ]
Haddock, M. G. [1 ]
Choo, C. R. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2015年 / 93卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2015.07.1088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2535
引用
收藏
页码：E213 / E214
页数：2
相关论文
共 50 条
  • [1] Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients
    Routman, David M.
    Funk, Ryan K.
    Stish, Bradley J.
    Mynderse, Lance A.
    Wilson, Torrence M.
    McLaren, Robert
    Harmsen, W. Scott
    Mara, Kristin
    Deufel, Christopher L.
    Furutani, Keith M.
    Haddock, Michael G.
    Pisansky, Thomas M.
    Choo, C. Richard
    Davis, Brian J.
    BRACHYTHERAPY, 2019, 18 (01) : 1 - 7
  • [2] Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer
    Moll, Matthias
    Renner, Andreas
    Kirisits, Christian
    Paschen, Christopher
    Zaharie, Alexandru
    Goldner, Gregor
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (11) : 986 - 992
  • [3] Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer
    Matthias Moll
    Andreas Renner
    Christian Kirisits
    Christopher Paschen
    Alexandru Zaharie
    Gregor Goldner
    Strahlentherapie und Onkologie, 2021, 197 : 986 - 992
  • [4] HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer
    Moreno Olmedo, E.
    Nagore, G.
    Suarez Gironzini, V.
    Minguez, C.
    Gomez, E.
    Garcia, A.
    Ciapa, V.
    Marrone, I.
    Lopez, E.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S1122 - S1123
  • [5] HDR Brachytherapy Monotherapy in patients with Low/Intermediate-risk Prostate Cancer
    Moreno Olmedo, E.
    Nagore, G.
    Suarez-Gironzini, V.
    Minguez, C.
    Gomez, E.
    Garcia, A.
    Ciapa, V.
    Marrone, I.
    Lopez, E.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S123 - S123
  • [6] Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy
    Anna Thi Huyen Tran
    Mandall, Paula
    Swindell, Ric
    Hoskin, P. J.
    Bottomley, David Martin
    Logue, John Paul
    Wylie, James Pinson
    RADIOTHERAPY AND ONCOLOGY, 2013, 109 (02) : 235 - 240
  • [7] The impact of neoadjuvant hormone therapy on the permanent 125I-seed brachytherapy for low- or intermediate-risk prostate cancer.
    Tanimoto, Ryuta
    Bekku, Kensuke
    Ebara, Shin
    Araki, Motoo
    Yanai, Hiroyuki
    Katayama, Norihisa
    Nasu, Yasutomo
    Kumon, Hiromi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [8] Biochemical outcomes for patients with intermediate-risk, organ-confined prostate cancer treated with I-125 interstitial brachytherapy monotherapy.
    Anna Thi Huyen Tran
    Mandall, Paula
    Swindell, Ric
    Hoskin, Peter
    Bottomley, David
    Wylie, James
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [9] Factors Predicting Outcome for Intermediate-Risk Prostate Cancer Patients Undergoing I-125 Brachytherapy With or Without External Beam Radiation Therapy
    Yorozu, A.
    Sutani, S.
    Kota, R.
    Saito, S.
    Toya, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E277 - E278
  • [10] A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
    Taussky, Daniel
    Ouellet, Veronique
    Delouya, Guila
    Saad, Fred
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (7-8): : 246 - 250
12345